Nevirapine versus Efavirenz

Non-nucleoside inhibitors of the HIV reversetranscriptase are now preferred to proteaseinhibitors (PI) for the treatment of HIV infection.Two main considerations account for this preference.The first is related to the low number of pillsand frequency of doses when treatment witheither nevirapine (NVP) or efavirenz (EFZ) is chosen.The second is related to the concern on agreater risk of lipodystrophy and lipid abnormalitiestaking PI, which could prone to cardiovascularevents in the near future.